Details for Patent: 6,656,935
✉ Email this page to a colleague
Which drugs does patent 6,656,935 protect, and when does it expire?
Patent 6,656,935 protects STENDRA and is included in one NDA.
This patent has forty-one patent family members in twenty-five countries.
Summary for Patent: 6,656,935
| Title: | Aromatic nitrogen-containing 6-membered cyclic compounds |
| Abstract: | An aromatic nitrogen-containing 6-membered cyclic compound of the formula (I): ##STR1## wherein Ring A is a substituted or unsubstituted nitrogen-containing heterocyclic group; R.sup.1 is a substituted or unsubstituted lower alkyl group, --NH--Q--R.sup.3 (R.sup.3 is a substituted or unsubstituted nitrogen containing heterocyclic group, and Q is a lower alkylene group or a single bond), or --NH--R.sup.4 (R.sup.4 is a substituted or unsubstituted cycloalkyl group); R.sup.2 is a substituted or unsubstituted aryl group; one of Y and Z is .dbd.CH--, and the other is .dbd.N--, or a pharmaceutically acceptable salt thereof, these compounds exhibiting excellent selective PDE V inhibitory activities, and hence, being useful in the prophylaxis or treatment of penile erectile dysfunction, etc. |
| Inventor(s): | Yamada; Koichiro (Saitama-ken, JP), Matsuki; Kenji (Saitama-ken, JP), Omori; Kenji (Saitama, JP), Kikkawa; Kohei (Kawaguchi, JP) |
| Assignee: | Tanabe Seiyaku Co., Ltd. (Osaka, JP) |
| Application Number: | 09/925,892 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,656,935 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
Drugs Protected by US Patent 6,656,935
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-001 | Apr 27, 2012 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF ERECTILE DYSFUNCTION | ⤷ Sign Up | |
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-002 | Apr 27, 2012 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF ERECTILE DYSFUNCTION | ⤷ Sign Up | |
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-003 | Apr 27, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF ERECTILE DYSFUNCTION | ⤷ Sign Up | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 6,656,935
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 11-261852 | Sep 16, 1999 |
| Japan | 2000-130371 | Apr 28, 2000 |
International Family Members for US Patent 6,656,935
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1219609 | ⤷ Sign Up | 92249 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 1219609 | ⤷ Sign Up | CA 2013 00040 | Denmark | ⤷ Sign Up |
| European Patent Office | 1219609 | ⤷ Sign Up | C300618 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1219609 | ⤷ Sign Up | 13C0050 | France | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
